Biotech News

Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth

Biofrontera Inc (BFRI)Biofrontera IncEarnings

Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended September 30, 2026.

Related news

Biofrontera Inc

Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines the topical photosensitizer Ameluz with RhodoLED red-light illumination systems. Actinic Keratosis Franchise Ameluz is established in actinic keratosis, a precancerous...

Recent company news

Stock data

Close
0.57 USD
Market cap
13.19M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States